other material
confidence high
sentiment positive
materiality 0.78
Corvus reports positive interim Phase 1 soquelitinib data in atopic dermatitis; $12.7M warrant exercise
Corvus Pharmaceuticals, Inc.
- Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.
- At Day 58, 90% of soquelitinib patients achieved EASI-50, 40% EASI-75, 10% EASI-90 vs 25%, 0%, 0% for placebo.
- No significant safety issues; only Grade 1 nausea (1 patient) and COVID-19 (1 patient) reported.
- Samlyn Capital exercised all warrants for 3,633,978 shares, generating ~$12.7M cash proceeds.
- Initial Cohort 2 data (200mg once daily) in 12 patients consistent with Cohort 1; no treatment-related AEs.